A mini review of nanosuspensions development

Journal of Drug Targeting

Volumn 20, Issue 3, 2012, Pages 209-223

  Liu, Yue ^a   Xie, Pengcheng ^b   Zhang, Dianrui ^a   Zhang, Qiang ^c  

^a SHANDONG UNIVERSITY   (China)

^b Chemical Engineering and Technology   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Discrimination; Nanosuspensions; Production techniques; Routes of administration; Special features; Stable measures

Indexed keywords

NANOCRYSTAL; SILIBININ; SOLVENT; STABILIZING AGENT;

ACID BASE BALANCE; ATOMIC FORCE MICROSCOPY; CYTOLOGY; DIFFUSION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; EMULSION; HUMAN; MEDIA MILLING; MICROFLUIDIC ANALYSIS; MICROFLUIDICS; NANOSUSPENSION; PRECIPITATION; PRIORITY JOURNAL; RELATIVE DENSITY; REVIEW; SOLIDIFICATION; SUSPENSION; ULTRASONICATION; ULTRASOUND; ZETA POTENTIAL;

ANIMALS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; HUMANS; NANOSTRUCTURES; NANOTECHNOLOGY; PHYSICOCHEMICAL PHENOMENA; SUSPENSIONS;

EID: 84863229909     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.645161     Document Type: Review

References (80)

1. Baert L, van 't Klooster G, Dries W, Fran?is M, Wouters A, Basstanie E, Iterbeke K, Stappers F, Stevens P, Schueller L, Van Remoortere P, Kraus G, Wigerinck P, Rosier J. (2009). Development of a longacting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm, 72, 502-508.
2. Ben Zirar S, Astier A, Muchow M, Gibaud S. (2008). Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. Eur J Pharm Biopharm, 70, 649-656.
3. Borner K, Hartwig H, Leitzke S, Hahn H, Müler RH, Ehlers S. (1999). HPLC determination of clofazimine in tissues and serum of mice after intravenous administration of nanocrystalline or liposomal formulations. Int J Antimicrob Agents, 11, 75-79.
4. Cerdeira AM, Mazzotti M, Gander B. (2010). Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability. Int J Pharm, 396, 210-218.
5. Chen H, Khemtong C, Yang X, Chang X, Gao J. (2011). Nanonization strategies for poorly water-soluble drugs. Drug Discov Today, 16, 354-360.
6. Chen RH, Tsai ML, Tseng LZ. (2009). Two-stage microfluidization combined with ultrafiltration treatment for chitosan mass production and molecular weight manipulation. Carbohyd Polym, 77, 767-772.
7. Chen JF, Wang YH, Guo F, Wang XM, Zheng C. (2000). Synthesis of nanoparticles with novel technology: high-gravity reactive precipitation. Ind Eng Chem Res, 39, 948-954.
8. Chen H, Wan J, Wang Y, Mou D, Liu H, Xu H, Yang X. (2008). A facile nanoaggregation strategy for oral delivery of hydrophobic drugs by utilizing acid-base neutralization reactions. Nanotechnology, 19, 375104.
9. Chen JF, Zheng C, Chen GT. (1996). Interaction of macro-and micromixing on particle size distribution in reaction precipitation. Chem Eng Sci, 51, 1957-1966.
10. Chen JF, Zhou MY, Shao L, Wang YY, Yun J, Chew NY, Chan HK. (2004). Feasibility of preparing nanodrugs by high-gravity reactive precipitation. Int J Pharm, 269, 267-274.
11. Chen JF, Zhou XM, Wang YH, Zheng C. (1998). Synthesis of ultrafine calcium carbonate. Chinese Patent No. ZL95105343.4.
12. Chen JF, Zhou XM, Zheng C. (1995). Ultrafine particle synthesis by high-gravity reactive precipitation. Chinese Patent No. 95105344.2.
13. Chiang PC, Alsup JW, Lai Y, Hu Y, Heyde BR, Tung D. (2009). Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery. Nanoscale Res Lett, 4, 254-261.
14. Das S, Suresh PK. (2011). Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B. Nanomedicine, 7, 242-247.
15. Dolenc A, Kristl J, Baumgartner S, Planinsek O. (2009). Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm, 376, 204-212.
16. Fakes MG, Vakkalagadda BJ, Qian F, Desikan S, Gandhi RB, Lai C, Hsieh A, Franchini MK, Toale H, Brown J. (2009). Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int J Pharm, 370, 167-174.
17. Feng FF, Zhang DR, Tian KL, Lou HY, Qi XL, Wang YC, Duan CX, Jia LJ, Wang FH, Liu Y, Zhang Q. (2011). Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by oridonin nanosuspension. Drug Deliv, 18, 265-271.
18. Fowler R. (1989). Higee-a status report. Chem Eng, 35, 456-473.
19. Formulation development and evaluation of metronidazole magnetic nanosuspension as a magnetic-targeted and polymericcontrolled drug delivery system. J Magn Magn Mater, 321, 1580-1585.
20. Gao Y, Li Z, Sun M, Li H, Guo C, Cui J, Li A, Cao F, Xi Y, Lou H, Zhai G. (2010). Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev Ind Pharm, 36, 1225-1234.
21. Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W. (2008b). Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm, 355, 321-327.
22. Guo K, Guo F, Feng YD, Chen JF, Zheng C, Gardner NC. (2000). Synchronous visual and RTD study on liquid ?ow inrotating packed-bed contactor. Chem Eng Sci, 55, 1699-1706.
23. Hancock BC, Parks M. (2000). What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res, 17, 397-404.
24. Hecq J, Deleers M, Fanara D, Vranckx H, Boulanger P, Le Lamer S, Amighi K. (2006). Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb- 35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm, 64, 360-368.
25. Jacobs C, Kayser O, Müler RH. (2001). Production and characterization of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int J Pharm, 214, 3-7.
26. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. (2007). Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm, 340, 126-133.
27. Kayser O. (2000). Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages. Int J Pharm, 196, 253-256.
28. Kayser O. (2001). A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int J Pharm, 214, 83-85.
29. Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL. (2003). Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm, 254, 73-75.
30. Kawashima Y, Lehr CM. (2001). Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther, 299, 775-781.
31. Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59, 631-644.
32. Kipp JE. (2004). The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm, 284, 109-122.
33. Kocbek P, Baumgartner S, Kristl J. (2006). Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm, 312, 179-186.
34. Kristl J, Dolenc A, Baumgartner S, Planinsek O. (2009). Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm, 376, 204-212.
35. Lai F, Sinico C, Ennas G, Marongiu F, Marongiu G, Fadda AM. (2009). Diclofenac nanosuspensions: influence of preparation procedure nd crystal form on drug dissolution behaviour. Int J Pharm, 373, 124-132.
36. Lamprecht A, Ubrich N, Yamamoto H, Schäer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. (2001). Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther, 299, 775-781.
37. Latha S, Selvamani P, Kumar CS, Sharavanan P, Suganya G, Beniwal VS, Rao PR. (2009). Formulation development and evaluation of metronidazole magnetic nanosuspension as a magnetic-targeted and polymeric-controlled drug delivery system. J Mang Mang Mater, 321, 1580-1585.
38. Lee J, Cheng Y. (2006). Critical freezing rate in freeze drying nanocrystal dispersions. J Control Release, 111, 185-192.
39. Lee RW, Mcshane J, Shaw JM, Wood RW. (2000). Particle size reduction. In: Liu R, ed. Water-Insoluble Drug Formation. Interpharm Press, Buffalo Grove, 455-492.
40. Liversidge GG, Cundy KC, Bishop J, Czekai D. (1992). Surface modified drug nanoparticles. US Patent 5145684.
41. Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X, Yu Z, Zhang D, Zhang Q. (2009). In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm, 379, 181-186.
42. Martien R, Loretz B, Sandbichler AM, Schnüch AB. (2008). Thiolated chitosan nanoparticles: transfection study in the Caco-2 differentiated cell culture. Nanotechnology, 19, 045101.
43. Mauludin R, Müler RH, Keck CM. (2009). Development of an oral rutin nanocrystal formulation. Int J Pharm, 370, 202-209.
44. Merisko-Liversidge E, Liversidge GG, Cooper ER. (2003). Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci, 18, 113-120.
45. Merisko-Liversidge E, McGurk SL, Liversidge GG. (2004). Insulin nanoparticles: a novel formulation approach for poorly water soluble Zn-insulin. Pharm Res, 21, 1545-1553.
46. Mishra PR, Al Shaal L, Müler RH, Keck CM. (2009). Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm, 371, 182-189.
47. Möchwitzer J, Achleitner G, Pomper H, Müler RH. (2004). Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm, 58, 615-619.
48. Mou D, Chen H, Wan J, Xu H, Yang X. (2011). Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Int J Pharm, 413, 237-244.
49. Muller RH. (1996). Zeta potential und Partikelladung-Kurze Theorie, praktische Meüdurchfuhrung. Stuttgart: Dateninterpretation, Wissenschaftliche
50. Muller RH, Becker R, Kruss B, Peters K. (1999). Pharmaceutical nanosuspensions for medicament administration as system ofincreased saturation solubility and rate of solution. US Patent 5858410.
51. Müler RH, Jacobs C. (2002). Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm, 237, 151-161.
52. Müler RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47, 3-19.
53. Muller RH, Keck CM. (2004). Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol, 113, 151-170.
54. Muller RH, Keck CM. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm, 62, 3-16.
55. Muller RH, Peters K. (1998). Nanosuspensions for the formulation of poorly soluble drugs-I. Preparation by a size-reduction technique. Int J Pharm, 160, 229-237.
56. Nam YS, Kang HS, Park JY, Park TG, Han SH, Chang IS. (2003). New micelle-like polymer aggregates made from PEI-PLGA diblock copolymers: micellar characteristics and cellular uptake. Biomaterials, 24, 2053-2059.
57. Ney P. (1974). Zetapotentiale und Flotierbarkeit von Mineralien. Wien: Springer.
58. Patravale VB, Date AA, Kulkarni RM. (2004). Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol, 56, 827-840.
59. Ponchel G, Montisci MJ, Dembri A. (1997). Mucoadhesion of colloidal particulate systems in the gasrointesinal tract. Eur J Pharm Biopharm, 4, 25-31
60. Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3, 785-796.
61. Rabinow B, Kipp J, Papadopoulos P, Wong J, Glosson J, Gass J, Sun CS, Wielgos T, White R, Cook C, Barker K, Wood K. (2007). Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm, 339, 251-260.
62. Sahoo SK, Dilnawaz F, Krishnakumar S. (2008). Nanotechnology in ocular drug delivery. Drug Discov Today, 13, 144-151.
63. Serajuddin AT. (1999). Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci, 88, 1058-1066.
64. Sun M, Gao Y, Pei Y, Guo C, Li H, Cao F, Yu A, Zhai G. (2010). Development of nanosuspension formulation for oral delivery of quercetin. J Biomed Nanotechnol, 6, 325-332.
65. Teeranachaideekul V, Junyaprasert VB, Souto EB, Müler RH. (2008). Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int J Pharm, 354, 227-234.
66. Thassu D, Deleers M, Pathak Y. (2007). Nanoparticulate drug delivery systems. Informa Healthcare USA, Inc.
67. Van den Mooter G, Van Eerdenbrugh B, Augustijns P. (2008a). Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm, 364, 64-75.
68. Van den Mooter G, Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P. (2008b). Drying of crystalline drug nanosuspensions-The importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci, 35, 127-135.
69. Verma S, Gokhale R, Burgess DJ. (2009a). A comparative study of topdown and bottom-up approaches for the preparation of micro/ nanosuspensions. Int J Pharm, 380, 216-222.
70. Verma S, Lan Y, Gokhale R, Burgess DJ. (2009b). Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm, 377, 185-198.
71. Wahlstrom JL, Chiang Po-Chang, Ghosh S, Warren CJ, Wene SP, A., Albin LA, Smith ME, Roberds SL. (2007). Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment. Nanoscale Res Lett, 2, 291-296.
72. Wang L, Liu Z, Liu D, Liu C, Juan Z, Zhang N. (2011a). Docetaxelloaded- lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm, 413, 194-201.
73. Wang Y, Liu Z, Zhang D, Gao X, Zhang X, Duan C, Jia L, Feng F, Huang Y, Shen Y, Zhang Q. (2011b). Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension. Colloids Surf B Biointerfaces, 83, 189-197.
74. Wang Y, Zhang D, Liu Z, Liu G, Duan C, Jia L, Feng F, Zhang X, Shi Y, Zhang Q. (2010). In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology, 21, 155104.
75. Weibel DB, Whitesides GM. (2006). Applications of microfluidics in chemical biology. Curr Opin Chem Biol, 10, 584-591.
76. Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y, Cui F. (2010). Preparation of stable nitrendipine nanosuspensions using the precipitationultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci, 40, 325-334.
77. Xiong R, Lu W, Li J, Wang P, Xu R, Chen T. (2008). Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int J Pharm, 350, 338-343.
78. Yang W, Johnston KP, Williams RO 3rd. (2010). Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm, 75, 33-41.
79. Zhao YX, Hua HY, Chang M, Liu WJ, Zhao Y, Liu HM. (2010). Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions. Int J Pharm, 392, 64-71.
80. Zheng D, Wang Y, Zhang D, Liu Z, Duan C, Jia L, Wang F, Liu Y, Liu G, Hao L, Zhang Q. (2011). In vitro antitumor activity of silybin nanosuspension in PC-3 cells. Cancer Lett, 307, 158-164.